Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Aetna Inc    AET

Delayed Quote. Delayed  - 10/21 10:02:00 pm
111.25 USD   +0.29%
10/18DJZenefits Touts New Software in Turnaround Effort
10/18 UnitedHealth sees more growth in 2017 when it exits Obamacare
10/13 AETNA : to Announce Third-Quarter 2016 Results
News SummaryMost relevantAll newsSector news 

Aetna Ready For 'Dual Eligibles' Despite Commercial Focus - CFO

share with twitter share with LinkedIn share with facebook
share via e-mail
03/19/2012 | 09:55pm CEST
   By Jon Kamp 

Aetna Inc. (>> Aetna Inc.) believes it can ably serve health-challenged patients covered by both Medicare and Medicaid, even though the company doesn't have a major stake in those markets.

Additionally, the commercially-focused health insurer doesn't need acquisitions to win business for "dual eligible" patients, according to Chief Financial Officer Joseph Zubretsky. Some of Aetna's big competitors have recently made deals with an eye on dual patients, and Aetna has faced questions about whether it has the right make-up for the market.

"I do believe we'll have the platforms built to be able to respond to this opportunity," Zubretsky said, speaking during an interview at Aetna's Hartford headquarters.

The market has significant potential, but will build over several years, giving Aetna time to grow its businesses from within, Zubretsky said. Meantime, Aetna has the capabilities within these businesses to address the kind of complex health problems dual patients often present, he said.

Dual patients, who represent a potential $300 billion market for health insurers, have become a hot topic as states and the federal government look for ways to better coordinate care and save money. These patients tend to rack up high costs due to their health challenges. A handful of states could have programs for covering dual patients up and running next year, and the market is expected to continue growing in subsequent years.

Managed-care companies could be big beneficiaries, but questions abound about which firms are best positioned to win state-by-state contracts. Analysts view Medicaid-focused insurers such as Molina Healthcare Inc. (>> Molina Healthcare, Inc.) and Centene Corp. (>> Centene Corp) as potential winners, and bigger insurers such as UnitedHealth Group Inc. (>> UnitedHealth Group Inc.) and WellPoint Inc. (WLP) are also expected to compete based on their presence in both the Medicaid and Medicare markets.

Aetna has modest stakes in markets for government-based plans. At the end of last year, roughly 90% of Aetna's 18.5 million medical members were on commercial health plan, which are typically plans provided through employers.

Citigroup analyst Carl McDonald recently said Aetna's valuation has been hurt by "the company's lack of government exposure". Still, Aetna shares are up 33% over the last year, helped by patients keeping a lid on health costs after the recession.

Competitors including UnitedHealth, WellPoint and Cigna Inc. (CI) have all recently made Medicare-focused acquisitions that could improve their chances in the duals market. Aetna has been wary of paying too much, however, and feels there is time to build up its own businesses.

"The opportunity has been reflected in certain managed care valuations long before the revenue is ever going to show up," Zubretsky said. "This is not a cataclysmic event where $300 billion dollars is going to race into the market inside of 12 months. It's going to happen in a phased approach."

Aetna Chief Executive Mark Bertolini has talked about the company's ability to grow its Medicare business by keeping commercial members on Aetna plans when they switch over to Medicare. There are about 1.2 million Medicare-eligible members in the company's commercial membership. He also noted Aetna has more than doubled revenue in its Medicaid business since acquiring it in 2007.

-By Jon Kamp, Dow Jones Newswires; 617-654-6728; jon.kamp@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AETNA INC
10/18DJZenefits Touts New Software in Turnaround Effort
10/18 UnitedHealth sees more growth in 2017 when it exits Obamacare
10/13 AETNA : to Announce Third-Quarter 2016 Results
10/13 AETNA INC (NYSE : AET), Merck & Co., Inc. (NYSE:MRK) Sign Value-Based Partnershi..
10/13 REGIONAL CANCER CARE ASSOCIATES : And Aetna Form Oncology Medical Home
10/12 AETNA : ’s Stars Are Shining as CMS Announces Medicare Quality Ratings
10/12DJHUMANA : Sees Potential Fallout From Lower Medicare Star-Rating Report
10/11 AETNA : and Merck Sign a Unique Value-Based Contract for Januvia® and Janumet®
10/11 AETNA INC : ex-dividend day
10/07 AETNA : Makes Resources Available to Members Affected by Hurricane Matthew
More news
Sector news : Managed Healthcare - NEC
10/21DJCIGNA : Ends Preauthorization for Medication to Treat Opioid Addiction
10/18DJUNITEDHEALTH : Tops Views, Boosts Outlook
10/18 UnitedHealth sees more growth in 2017 when it exits Obamacare
10/18 UNITEDHEALTH : CEO sees earnings growth continuing into 2017
10/12DJHUMANA : Sees Potential Fallout From Lower Medicare Star-Rating Report--3rd Upda..
More sector news : Managed Healthcare - NEC
News from SeekingAlpha
10/17 Health Insurance Companies To Hike Prices Now, Suffer Later
10/01 Dividend Champions For October 2016
09/30 Aetna declares $0.25 dividend
09/29 AETNA SUBSIDIZING APPLE WATCH : Fitbit gets downgrade
09/12 EVOLENT HEALTH : Because The Argument For Value-Based Care Is Getting Stronger
Financials ($)
Sales 2016 63 255 M
EBIT 2016 4 945 M
Net income 2016 2 583 M
Debt 2016 4 521 M
Yield 2016 0,90%
P/E ratio 2016 15,20
P/E ratio 2017 13,54
EV / Sales 2016 0,69x
EV / Sales 2017 0,64x
Capitalization 39 027 M
More Financials
Duration : Period :
Aetna Inc Technical Analysis Chart | AET | US00817Y1082 | 4-Traders
Full-screen chart
Technical analysis trends AETNA INC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 137 $
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Mark T. Bertolini Chairman & Chief Executive Officer
Karen S. Lynch President
Margaret M. McCarthy Executive Vice President-Operations & Technology
Shawn M. Guertin CFO, Executive VP & Chief Enterprise Risk Officer
Harold L. Paz Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AETNA INC2.89%39 027
ANTHEM INC-11.43%32 502
HUMANA INC-1.47%26 218
CENTENE CORP-5.64%10 603
More Results